Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment

Chris Sidey-Gibbons, PhD1; André Pfob2; Malke Asaad, MD3; Stefanos Boukovalas, MD3; Yu-Li Lin, MA4; Jesse Creed Selber, MD, MPH3; Charles E. Butler, MD3; and Anaeze Chidiebele Offodile II, MD, MPH3,4,5,6

abstract

PURPOSE Financial burden caused by cancer treatment is associated with material loss, distress, and poorer outcomes. Financial resources exist to support patients but identification of need is difficult. We sought to develop and test a tool to accurately predict an individual’s risk of financial toxicity based on clinical, demographic, and patient-reported data prior to initiation of breast cancer treatment.

PATIENTS AND METHODS We surveyed 611 patients undergoing breast cancer therapy at MD Anderson Cancer Center. We collected data using the validated COmprehensive Score for financial Toxicity (COST) patient-reported outcome measure alongside other financial indicators (credit score, income, and insurance status). We also collected clinical and perioperative data. We trained and tested an ensemble of machine learning (ML) algorithms (neural network, regularized linear model, support vector machines, and a classification tree) to predict financial toxicity. Data were randomly partitioned into training and test samples (2:1 ratio). Predictive performance was assessed using area-under-the-receiver-operating-characteristics-curve (AUROC), accuracy, sensitivity, and specificity.

RESULTS In our test sample (N = 203), 48 of 203 women (23.6%) reported significant financial burden. The algorithm ensemble performed well to predict financial burden with an AUROC of 0.85, accuracy of 0.82, sensitivity of 0.85, and specificity of 0.81. Key clinical predictors of financial burden from the linear model were neoadjuvant therapy (βregularized, .11) and autologous, rather than implant-based, reconstruction (βregularized, .06). Notably, radiation and clinical tumor stage had no effect on financial burden.

CONCLUSION ML models accurately predicted financial toxicity related to breast cancer treatment. These predictions may inform decision making and care planning to avoid financial distress during cancer treatment or enable targeted financial support. Further research is warranted to validate this tool and assess applicability for other types of cancer.

JCO Clin Cancer Inform 5:338-347. © 2021 by American Society of Clinical Oncology

INTRODUCTION Over the past decade, increasing public and policy attention has been paid to the issue of high treatment-associated costs for cancer. Cancer is currently the second most expensive chronic condition with an annual outlay estimated to be $157 billion in US dollars in 2020.1 The term financial toxicity denotes the deleterious effects of cancer treatment costs on the subjective and material experience of patients with cancer.2,3 Financial toxicity has been associated with worsening oncologic, psychosocial, and economic outcomes across several cancer types.3,4 According to recent estimates, 48%-73% of cancer survivors experience some ill effects of financial toxicity.5 Breast cancer has become the representative condition for financial toxicity in cancer owing to its annual incidence, public health awareness, and policy relevance.6,9 Although the etiology is multifactorial, there is limited evidence surrounding the patient- and treatment-level risk factors associated with financial toxicity among breast cancer surgical patients. Of note, much of the existing literature on financial toxicity is centered on the medical oncology experience.3 This is salient because over 60% of index breast cancer presentations are early-stage and therefore amenable to surgical treatment.10

The 11-item COmprehensive Score for financial Toxicity (COST) questionnaire is a cancer-specific, prospectively validated patient-reported outcome measure (PROM) that provides insights into the manifestations of treatment costs-associated financial distress.11,12 Precise identification of at-risk population segments may enable targeted financial support.
CONCEPT

Key Objective
Can machine learning (ML) algorithms predict treatment-associated financial toxicity in patients with breast cancer who undergo surgical treatment by using clinical, demographic, and patient-reported data?

Knowledge Generated
The algorithm performed well to predict financial burden with an area-under-the-receiver-operating-characteristics-curve of 0.85 and a sensitivity of 0.85. Key clinical predictors of financial burden were neoadjuvant chemotherapy and autologous rather than implant-based breast reconstruction.

Relevance
ML models accurately predicted financial toxicity related to breast cancer treatment. These predictions may inform decision making and care planning to mitigate financial distress during cancer treatment or enable targeted financial support.

However, an accurate prediction of which individual patient will experience financial toxicity is inherently challenging. This is because financial toxicity is a complex interplay of patient demographic, disease level, and treatment-related factors. Machine learning (ML) may help clinicians and health systems overcome this challenge. ML is a branch of artificial intelligence that leverages automated mathematical model creation to iteratively learn from input data, resulting in the identification and/or prediction of a future state.13-16 ML algorithms may help identify which complex combination of patient and treatment characteristics make it more likely to experience financial toxicity by comparing those patients with financial toxicity to those without financial toxicity during the training process of the algorithm. Less complex ML algorithms (eg, regularized regression) are readily interpretable but their performance is limited to identifying linear intervariable relations; more complex ML algorithms (eg, classification trees, support vector machines [SVMs], and neural networks) can identify nonlinear intervariable relations but are less comprehensible.14,16 In the present article, we explore whether supervised ML algorithms can reliably predict financial toxicity in patients with breast cancer who undergo surgical treatment. These predictions may inform decision making and care planning to avoid financial distress during cancer treatment or enable targeted financial support for individuals.

PATIENTS AND METHODS

Data Source
The University of Texas, MD Anderson Cancer Center’s Institutional Review Board approved the present study. This is a single-institution cross-sectional survey of consecutive adult female patients who underwent lumpectomy or mastectomy (skin-sparing, total, nipple-sparing, or modified radical) over an 18-month period (January 2018-June 2019). All human participants provided written informed consent. All eligible procedures were performed under the indication of cancer or risk reduction (ie, BRCA mutation).

Inclusion criteria were age > 18 years and the ability to comprehend our survey in English. Our electronic survey, with an embedded consent form, was deployed to the patient population (N = 2,293) on June 2019. Nonresponses triggered three email reminders. The survey comprised the COST questionnaire and a purpose-built 30-item questionnaire that elicited patient-reported information on several domains shown to be relevant to financial hardship in cancer.3 The COST questionnaire is well represented in the health services research literature and has been described previously.11,12,17-20 A total of 2,283 patients participated in the survey; 611 patients (26.6%) completed the survey and were used in our analytical sample.

Candidate Covariates
Table 1 outlines the baseline demographic information and covariates related to treatment course that were abstracted from the purpose-built survey and attendant electronic medical record (EMR), respectively. These patient- and treatment-level factors were selected for their ability to engender the construction of a prediction tool to facilitate pre-operative risk facilitation for financial toxicity.

Missing Data
Missing data were computed using multivariate imputation by chained equations.21 There were 1% of missing values in the data set—there were no missing values in the outcome variable.

Outcome
The primary outcome was the ensemble’s ability to accurately identify women who experienced high financial burden. We defined financial burden as a COST score ≤ 23. Briefly, the COST questionnaire is scored from 0 to 44, and lower values represent greater treatment-induced financial distress. This cutoff was both commensurate with (1) previous research using the measure11,17 and (2) an average COST score of 23 for those women who responded that they experienced significant financial burden on a single-item question we added to the questionnaire. Finally, this cutoff engendered a more robust analysis as the median COST score for our population was 28.
TABLE 1. Variables Used for Algorithm Development.

| Variable          | Classification | Definition                                                                 |
|-------------------|----------------|-----------------------------------------------------------------------------|
| Age               | Numeric        | Patient’s age at the time of diagnosis                                       |
| Diabetes          | Yes or no      | Previously diagnosed diabetes                                                |
| Chemotherapy      | Either         | Chemotherapy received as part of breast cancer treatment                     |
|                   | (1) Neoadjuvant|                                                                             |
|                   | (2) Adjuvant   |                                                                             |
|                   | (3) Both       |                                                                             |
| Radiotherapy      | Either         | Radiotherapy received as part of breast cancer treatment                     |
|                   | (1) Pre-operative|                                                                      |
|                   | (2) Post-operative|                                                       |
|                   | (3) None       |                                                                             |
| Hormonal therapy  | Either         | Hormonal therapy received as part of breast cancer treatment                 |
|                   | (1) Neoadjuvant|                                                                             |
|                   | (2) Adjuvant   |                                                                             |
|                   | (3) Both       |                                                                             |
| Breast surgery    | Either         | Surgical therapy received as part of breast cancer treatment                 |
|                   | (1) Lumpectomy |                                                                             |
|                   | (2) Mastectomy |                                                                             |
|                   | (3) Both       |                                                                             |
| Breast reconstruction | Either | Type of breast reconstruction if the patient underwent mastectomy         |
|                   | (1) Implant-based|                                                           |
|                   | (2) Autologous |                                                                             |
|                   | (3) Both       |                                                                             |
| Credit score      | Either         | Credit score as reported by the patient                                      |
|                   | (1) Poor       |                                                                             |
|                   | (2) Fair       |                                                                             |
|                   | (3) Average    |                                                                             |
|                   | (4) Good       |                                                                             |
|                   | (5) Excellent  |                                                                             |
|                   | (6) Prefer not to say |                                                       |
| Cancer stage      | Either         | Breast cancer stage according to AJCC (American Joint Committee on Cancer)   |
|                   | (1) 0          |                                                                             |
|                   | (2) Ia         |                                                                             |
|                   | (3) Ib         |                                                                             |
|                   | (4) Ila        |                                                                             |
|                   | (5) Ilb        |                                                                             |
|                   | (6) Iiia       |                                                                             |
|                   | (7) Ilbb       |                                                                             |
|                   | (8) Iic        |                                                                             |
|                   | (9) IV         |                                                                             |
| Health insurance  | Either         | Type of health insurance as reported by the patient                          |
|                   | (1) Medicare   |                                                                             |
|                   | (2) Medicaid   |                                                                             |
|                   | (3) Commercial |                                                                             |
| Ethnicity         | Either         | Ethnicity as reported by the patient                                         |
|                   | (1) African American|                                                   |
|                   | (2) Caucasian  |                                                                             |
|                   | (3) Hispanic   |                                                                             |
|                   | (4) Asian      |                                                                             |
|                   | (5) Native American|                                                      |
|                   | (6) Other      |                                                                             |
| Annual income     | Either         | Annual income as reported by the patient                                      |
|                   | (1) < $20,000 USD |                                                             |
|                   | (2) $20,000-$39,999 USD |                                             |
|                   | (3) $40,000-$59,999 USD |                                             |
|                   | (4) $60,000-$79,999 USD |                                             |
|                   | (5) $80,000-$99,999 USD |                                             |
|                   | (6) $100,000-$119,999 USD |                                             |
|                   | (7) $120,000-$139,999 USD |                                             |
|                   | (8) > $140,000 USD |                                             |
| Employment        | Yes or no      | Employment at the time of diagnosis                                           |

Abbreviation: USD, United States dollar.

*Variables dichotomized were methodologically necessary.

Statistical Analysis

The development of our algorithms was informed by guidelines on how to use ML in medicine and diagnostic tests as well as previously published research by our group. We provide a detailed description of the algorithm development according to these guidelines in the Data Supplement. We used the Prediction Model Study Risk of Bias Assessment Tool (PROBAST) to ensure high accuracy when these models were used elsewhere. We normalized the range of all values using feature scaling. We then trained and tested four ML algorithms (neural network, regularized regression, SVMs, and regression trees) using the open-source R statistical programming software (RStudio, Boston, MA). Four algorithms were selected based on their demonstrated high performance on similar predictive tasks. Algorithms are introduced briefly below, and details on the algorithm development are published elsewhere and in the Data Supplement.

**Regularized regression using the elastic net.** Regularized logistic regression is a type of regression where the regularization process effectively selects features to include in the model ensuring that the model has a reduced risk of bias and increased likelihood of generalizability to new data sets. Aside from improved generalizability, the regularized regression provides coefficients that can be interpreted to understand why the model is making the decisions it is making (Table 4).

**Classification tree.** Classification trees are algorithms that use recursive partitioning of data to fit a simple prediction model with a single rule (eg, is body mass index (BMI) > 30) at each partition node (Fig 2). The tree comprised multiple decision nodes that guide the algorithm toward the correct classification. Classification trees are capable of providing both a clearly interpretable decision-making process as well as modeling more complex nonlinear relationships between predictors and outcomes, which is why we have selected this algorithm for our analysis to predict financial toxicity.

**Support vector machines.** SVMs are binary classifier algorithms that seek to create a linear boundary that separates classes in a high-dimensional feature space. To successfully create linear separators (known as hyperplanes) within complex nonlinear data sets, SVMs use a technique known as a kernel trick. The kernel trick allows the algorithm to transform the input data to straighten out the complexity and to allow a linear hyperplane to separate the classes (eg, will a patient experience financial toxicity or not).

**Neural network.** Neural networks are complex algorithms inspired by the structure of the human brain and consist of connected units (neurons). Similar to the human brain, neural networks operate by sending signals throughout their architecture, which are combined and modified at each neuron before proceeding through the entire architecture of
the network and, eventually, leading to a decision. Neural networks can process large amounts of unstructured data and identify the most distinct patterns—as we do not know all possible influencing variables yet in the prediction of financial toxicity, we also used this algorithm for our analysis.14,16

We combined predictions from each of the individual algorithms into a voting ensemble to derive final predictions of financial burden.16 Data were randomly partitioned into training and test samples with a 2:1 ratio. Metrics used for model performance assessment were overall accuracy, sensitivity (correctly identified women who would experience financial toxicity), specificity (correctly identified women who would not experience financial toxicity), and area-under-the-receiver-operating-characteristics-curve (AUROC).

RESULTS

Patients

The 611 patients in the full analysis set were randomly partitioned (2:1 ratio) into a training set for the algorithm development (n = 408) and a test set (n = 203). The mean age at baseline was 58 ± 12 years and BMI was 28.7 ± 6.5. Caucasians were the predominant racial category (76.8%), and 60% of patients reported an annual income > $80,000 in US dollars. The most common clinical tumor category was stage I in 273 women (44.7%), and most women (55.5%) did not receive chemotherapy (neoadjuvant or adjuvant). Fifty-seven percent of patients underwent lumpectomy and 61% of patients received adjuvant hormonal therapy. Regarding the effect of financial toxicity on patients, 367 (40.1%) at least once decreased their basic spending on things such as food and clothing; 412 (67.5%) at least once decreased their spending on leisure activities such as vacations, eating out, or movies; 38 (6.2%) delayed breast surgery because of concern about costs; and 75 (12.3%) skipped a clinic visit (oncology, breast surgery, and plastic surgery) to save on costs. Complete baseline demographic and clinical characteristics are outlined in Table 2.

Algorithm Performance

When applied to baseline data, the algorithm reliably predicted women who would later experience financial burden because of treatment (Table 3). In the test set of 203 women, the overall accuracy of the algorithm ensemble was 0.82 (95% CI, 0.76 to 0.87). The algorithm ensemble correctly identified 41 of 48 women who later experienced financial burden (sensitivity = 0.85; 95% CI, 0.72 to 0.94), and 125 of 155 without a financial burden (specificity = 0.81; 95% CI, 0.74 to 0.87). Combining the predictions of the four single algorithms into a voting ensemble improved sensitivity to predict financial toxicity. Of the single algorithms, the neural network showed highest sensitivity (64.6%; 95% CI 49.5 to 77.8). The area under the ROC curve for the algorithm ensemble was 0.85 (95% CI, 0.79 to 0.91). ROC curves are shown in Figure 1.

Factors Associated with Financial Burden

We analyzed the coefficients in the regularized regression model (Table 4) and the classification tree. The following were identified as being key clinical predictors of financial burden in both models: neoadjuvant therapy (βregularized, .11) and low credit score (βregularized, .22). With respect to the latter, an inverse relationship between worsening credit score and risk of financial burden was also appreciated, that is, poor credit score (βregularized, .05), fair (βregularized, .05), good (βregularized, −.02), and excellent (βregularized, −.09). Both Medicare and Medicaid insurance lowered the risk of financial burden and African Americans were noted to be at higher risk to experience financial burden (βregularized, .01) relative to Caucasians (βregularized, .00). In the regularized regression model, the receipt of autologous reconstruction was a key predictor of financial toxicity (βregularized, .06). Notably, radiation and clinical tumor stage had no apparent effect on financial burden in either model. The classification tree is shown in Figure 2.

Analysis of Misclassified Patients

There were seven cases (14.6%) where the algorithm incorrectly predicted that financial burden would not be experienced when in fact it was. The Data Supplement compares the characteristics of the seven misclassified patients to the whole cohort. These patients had a lower cost score (15.6 v 28.0), a higher incidence of major complications (28.6% v 7.5%), were less likely to be employed (57.1% v 62.5%), and younger (mean age 53 years v 58 years).

DISCUSSION

In the present study, we demonstrate that the occurrence of financial toxicity can be accurately predicted prior to the initiation of treatment using ML algorithms trained on patient-reported, perioperative, and clinical data. Evaluation of algorithms suggested that receipt of neoadjuvant chemotherapy, utilization of autologous breast reconstruction, and a low credit score as being significantly associated with a risk of financial toxicity. Our supervised learning algorithm demonstrated good discriminatory performance with an AUROC of 0.85, accuracy of 0.82, sensitivity of 0.85, and specificity of 0.81. Our intent with the present study was to establish a methodologic framework for (1) making financial toxicity actionable (ie, target for interventions) and (2) embedding financial toxicity assessment into clinical workflows (eg, artificial intelligence algorithms integrated into EMRs can flag high-risk patients at the time of pre-operative appointments).

It is clear that advances in breast cancer treatment have yielded measurable gains in clinical outcomes for these patients.10 Unfortunately, they have also led to undue...
| Characteristic | Value |
|----------------|-------|
| Mean age (SD), years | 58.4 (12.2) |
| Age, no. (%) | |
| < 30 years | 6 (1.0) |
| 30-50 years | 158 (25.9) |
| 51-70 years | 343 (56.1) |
| > 70 years | 104 (17.0) |
| Cancer stage (according to AJCC), no. (%) | |
| Stage 0 | 148 (24.2) |
| Stage 0-DCIS | 113 (76.4) |
| Stage 0-BRCA mutation, prophylactic mastectomy | 22 (14.9) |
| Stage 0-other risk reducing surgery | 13 (8.8) |
| Stage Ia | 223 (36.5) |
| Stage Ib | 50 (8.2) |
| Stage Iib | 77 (12.6) |
| Stage Iib | 44 (7.2) |
| Stage IIIa | 18 (2.9) |
| Stage IIIb | 16 (2.6) |
| Stage IIIc | 28 (4.6) |
| Stage IV | 7 (1.1) |
| Chemotherapy, no. (%) | |
| None | 339 (55.5) |
| Neoadjuvant | 114 (18.7) |
| Adjuvant | 92 (15.1) |
| Both | 66 (10.8) |
| Hormonal therapy, no. (%) | |
| None | 214 (35.0) |
| Neoadjuvant | 3 (0.5) |
| Adjuvant | 373 (61.0) |
| Both | 21 (3.4) |
| Radiation therapy, no. (%) | |
| Yes | 403 (65.8) |
| No | 208 (34.0) |
| Surgical therapy, no. (%) | |
| Lumpectomy | 351 (57.4) |
| Mastectomy | 260 (42.6) |
| Type of breast reconstruction after mastectomy, no. (%) | |
| Implant-based | 116 (44.6) |
| Autologous | 49 (18.8) |
| Mixed | 6 (2.3) |
| None | 89 (34.2) |
| Credit score, no. (%) | |
| Poor | 25 (4.1) |
| Fair | 41 (6.7) |

(Continued in next column)
Financial burden for patients, their families, and the larger society. Financial toxicity is a well-described sequelae of contemporary cancer treatment that has been shown to incite the following adverse effects: worse health-related quality of life,\textsuperscript{2,26} treatment nonadherence,\textsuperscript{27} employment disruption,\textsuperscript{28} bankruptcy,\textsuperscript{4} early mortality,\textsuperscript{29} and maladaptive behaviors.\textsuperscript{27} Examples of maladaptive behaviors intended to lower costs include skipping clinic visits, reducing medication doses, and adjustments in nonmedical spending (travel, food, education, and clothing).\textsuperscript{2,3,17} Recent evidence has also shown that women of lower socioeconomic status prioritize treatment costs over certain aspects of their cancer care such as receipt of reconstruction.\textsuperscript{30,31}

Strategies to mitigate financial toxicity include provider education, deployment of financial navigators, and increasing access to copay assistance and charity care programs.\textsuperscript{1} In the absence of a financial toxicity prediction algorithm to appropriately subsegment or identify high-risk patients with breast cancer, the expense and indirect costs of implementing these mitigation strategies at scale (ie, deployed to every patient with breast cancer) would be prohibitive. Thus, ML algorithms may be a powerful instrument that reliably predicts the future experience of financial toxicity: it would allow the care team to (a) subsegment patients with breast cancer into high-risk populations for financial toxicity based on predicted COST score, (b) tailor the deployment of financial toxicity mitigation tools to this population, for example, financial navigators, charity aid, or insurance copay assistance programs, and (c) guide shared decision making with respect to high-risk patient populations to align treatment decisions with their preferences and values. Additionally, accurate predictions of financial toxicity may also guide the development and implementation of personalized treatment strategies concordant with the values and healthcare spending preferences of patients.\textsuperscript{32}

Given the immense societal and policy salience of financial toxicity, risk-factor identification among surgical patients has become an area of considerable research focus.\textsuperscript{18,30,33,34} Our aforementioned results that identified neoadjuvant chemotherapy and poor credit as significant financial toxicity risk factors have been leveraged to train and test several different ML algorithms. Table 3 provides an evaluation of these algorithms, which suggests that the ensemble of all algorithms would be the most efficacious as determined by its accuracy, sensitivity, and AUC.

Table 3. Evaluation of Algorithms Trained to Predict Financial Toxicity

| Algorithm              | Accuracy, % (No.); (95% CI) | Sensitivity, % (No.); (95% CI) | AUC (95% CI) |
|------------------------|-----------------------------|--------------------------------|--------------|
| Regularized regression | 83.2% (169 of 203) (77.4% to 88.1%) | 58.3% (20 of 48) (27.6 to 56.8) | 0.87 (0.82 to 0.92) |
| Classification tree    | 75.9% (154 of 203) (69.5% to 81.6%) | 6.3% (3 of 48) (1.3% to 17.2%) | 0.76 (0.68 to 0.84) |
| Support vector machine | 79.8% (162 of 203) (73.6% to 85.1%) | 27.1% (13 of 48) (15.3% to 41.8%) | 0.79 (0.72 to 0.85) |
| Neural network         | 81.8% (166 of 203) (75.8% to 86.8%) | 64.6% (31 of 48) (49.5% to 77.8%) | 0.85 (0.79 to 0.90) |
| Ensemble of all algorithms | 81.2% (166 of 203) (75.8% to 86.9%) | 85.4% (41 of 48) (72.2% to 93.9%) | 0.85 (0.79 to 0.91) |

Abbreviation: AUC, area under the receiver operating characteristic curve.

Given the immense societal and policy salience of financial toxicity, risk-factor identification among surgical patients has become an area of considerable research focus.\textsuperscript{18,30,33,34} Our aforementioned results that identified neoadjuvant chemotherapy and poor credit as significant financial toxicity risk factors have been leveraged to train and test several different ML algorithms. Table 3 provides an evaluation of these algorithms, which suggests that the ensemble of all algorithms would be the most efficacious as determined by its accuracy, sensitivity, and AUC.

FIG 1. Receiver operating characteristics curves for the machine learning algorithms.
factors are not unexpected and in line with the extant literature. A 2019 systematic review by Lee et al. identified chemotherapy as an independent risk factor for financial toxicity, whereas radiation therapy and ablative surgery were not consistently associated with increased risk.35

In a 2018 study by Dean et al., poor self-reported credit quality was identified as a marker of economic burden, perceived stress, and worsening overall mental and physical health in breast cancer survivors.36 Our work expands on this association through the use of a validated instrument (ie, COST score), a robust analytical approach, and larger study cohort. More importantly, it draws attention to the possible utility of credit score surveillance as a screening tool for early referral to financial counselors and social work.3

Our finding that autologous reconstruction is associated with an increased risk of financial toxicity compared with implant-based reconstruction warrants further investigation in light of evidence of increased utilization rates in the United States.37 Breast reconstruction decisions are highly preference-sensitive in relation to both the indication and subtype pursued. Financial toxicity, therefore, introduces a new patient-borne dimension to the evaluation of these two healthcare interventions. Prospective studies are needed to (a) validate this finding and (b) query its influence on the decision to undergo autologous breast reconstruction.

Our study is subject to several limitations that warrant mention. First, it was performed at a single, quaternary care institution that may not be representative of other patients with breast cancer or oncology practices. Prospective, multicenter studies involving diverse populations will be needed to verify the validity and generalizability of our algorithm prior to any consideration for implementation into clinical workflows.13 Second, the cross-sectional nature of our survey introduces variability in data completeness and limits the veracity of our analysis. Third, the survey components that are dependent on self-reported data might generate some imprecision in our estimates. Fourth,

**TABLE 4.** Factors Associated With Financial Toxicity Upon Regularized Regression

| Characteristic                                      | Regularized Coefficient for Financial Toxicity (Positive Values Indicate a Positive Correlation With Financial Toxicity) |
|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Age                                                 | 0.0                                                                   |
| Diabetes                                            | 0.05                                                                 |
| Smoker                                              | 0.0                                                                   |
| Cancer stage (according to AJCC), no. (%)           |                                                                       |
| Stage 0                                             | 0.0                                                                   |
| Stage Ia                                            | 0.0                                                                   |
| Stage Ib                                            | 0.0                                                                   |
| Stage IIA                                           | 0.0                                                                   |
| Stage IIB                                           | 0.0                                                                   |
| Stage IIIa                                          | 0.0                                                                   |
| Stage IIIb                                          | 0.0                                                                   |
| Stage IIIc                                          | 0.0                                                                   |
| Stage IV                                            | 0.0                                                                   |
| Chemotherapy, no. (%)                               |                                                                       |
| Neoadjuvant                                         | 0.11                                                                  |
| Adjuvant                                            | 0.09                                                                  |
| Both                                                | 0.0                                                                   |
| Hormonal therapy, no. (%)                           |                                                                       |
| Neoadjuvant                                         | 0.01                                                                  |
| Adjuvant                                            | 0.01                                                                  |
| Both                                                | 0.0                                                                   |
| Radiation therapy                                   | 0.0                                                                   |
| Surgical therapy, no. (%)                           |                                                                       |
| Lumpectomy                                          | 0.0                                                                   |
| Mastectomy                                          | 0.0                                                                   |
| Type of breast reconstruction after mastectomy      |                                                                       |
| Implant-based                                       | 0.0                                                                   |
| Autologous                                          | 0.06                                                                  |
| Mixed                                               | 0.0                                                                   |
| Credit score, no. (%)                               |                                                                       |
| Poor                                                | 0.22                                                                  |
| Fair                                                | 0.05                                                                  |
| Average                                             | 0.05                                                                  |
| Good                                                | −0.02                                                                 |
| Excellent                                           | −0.09                                                                 |
| Type of insurance, no. (%)                          |                                                                       |
| Medicare                                            | −0.07                                                                 |
| Medicaid                                            | 0.0                                                                   |
| Commercial                                          | 0.0                                                                   |

(Continued in next column)
although we agree that a prediction accuracy of 82% is not optimal, it still represents a marked improvement over the current standard of care, which is an unstructured and nonsystematic approach (ie, clinician intuition) of assessing the risk of financial toxicity in patients with breast cancer. Furthermore, it is performed in a retrospective fashion (ie, after the end of treatment) that dampens the utility and overall effectiveness of reducing financial toxicity in the first place (see above). However, our algorithm failed to predict financial toxicity in seven (15%) cases. In-person analysis (Data Supplement) revealed that these patients had a higher incidence of major complications (28.6% v 7.5%) likely driven by a higher predisposition toward obesity and diabetes. Complications have been shown in prior studies to result in significant personal financial burden after cancer surgery.\textsuperscript{3,38} Additionally, our misclassified patient segment was less likely to be employed (57.1% v 62.5%) at the time of diagnosis. A synergistic effect between these two risk factors (unemployment and increased complications) for financial toxicity, identified in other studies,\textsuperscript{3} may have led to their misclassification. Predictive performance of our algorithm may have also limited by unmeasured confounders. More detailed information (eg, about the molecular subtype of breast cancer or radiation therapy) may allow for more accurate predictions of the model. Future prospective, multicenter research is indicated to overcome this limitation. Moreover, qualitative approaches among the patients who were misclassified by our algorithm may help to identify additional relevant variables in the prediction of financial toxicity. Fifth, as there is no conceptual framework for financial toxicity grading yet, our algorithm does not
incorporate different financial toxicity grades. We hope to address financial toxicity grades in future model iterations. Sixth, our survey response rate of 28% can also lead to selection bias because of systematic differences between responders and nonresponders. However, we observed a good distribution of COST scores (financial toxicity) among these 28% who responded to the survey, which minimizes possible response bias. Seventh, the discriminative performance of the single four algorithms was heterogenous with AUC values ranging from 0.76 (95% CI, 0.68 to 0.84) for the regression tree algorithm and 0.87 (95% CI, 0.82 to 0.92) for the regularized regression algorithm. Sensitivity to toxicity among the same patient group and the combination into a voting ensemble improved the prediction of financial toxicity. This is an interesting finding as it implies that different ML algorithms actually identified different patterns for financial toxicity among the same patient group and the combination into a voting ensemble has further improved this pattern identification.

Several strengths can also be identified in the present study. First, to the best of our knowledge, ours is the first report in the literature of the deployment of an ML algorithm for financial toxicity prediction. Additionally, our use of a condition-specific PROM (ie, COST tool) and discriminative algorithms facilitate robustness in our results.

In conclusion, ML provides a set of powerful tools that have the potential to facilitate individualized data-driven, shared decision making in breast cancer care. ASCO has already asserted that financial considerations be included in the cancer treatment planning process. This is most germane in early-stage breast cancer wherein there are multiple surgical treatment options with comparable efficacy but different cost profiles. ML techniques can be used to develop a clinical decision-support aid for patients undergoing mastectomy or breast conservation therapy. This allows for (a) optimization of peri-operative counseling, (b) timely referral to financial navigators, and (c) a more patient-centered delivery paradigm. Our research provides evidence that ML models applied to baseline data can accurately predict the future experience of financial toxicity related to breast cancer treatment. Considering the rising costs of cancer care, the potential for individualized data-driven predictions of financial burden holds enormous promise for the creation of a learning health system in oncology.

AFFILIATIONS
1Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Obstetrics and Gynecology, Heidelberg University, Heidelberg, Germany
3Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX
5Institute for Cancer Care Innovation, University of Texas MD Anderson Cancer Center, Houston, TX
6Baker Institute for Public Policy, Rice University, Houston, TX

CORRESPONDING AUTHOR
Chris Sidey-Gibbons, PhD, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; Twitter: @DrCGibbons; @andrepfob; @anaeze_offodile; e-mail: cgibbons@mdanderson.org.

DISCLAIMER
The research protocol was approved by the institutional review board and ethics committee. All human participants provided written informed consent.

PRIOR PRESENTATION
Presented at the ASCO 2020 Virtual Annual Meeting, May 29-June 1, 2020.

SUPPORT
Supported by University Cancer Foundation via Sister Institution Network Fund at the University of Texas MD Anderson Cancer Center.

AUTHOR CONTRIBUTIONS
Conception and design: Chris Sidey-Gibbons, André Pfob, Malke Asaad, Jesse Creed Selber, Anaeze Chidiebele Offodile II
Financial support: Anaeze Chidiebele Offodile II
Collection and assembly of data: Chris Sidey-Gibbons, Malke Asaad, Stefanos Boukovalas, Anaeze Chidiebele Offodile II
Data analysis and interpretation: Chris Sidey-Gibbons, André Pfob, Malke Asaad, Stefanos Boukovalas, Yu-Li Lin, Charles E. Butler, Anaeze Chidiebele Offodile II
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Yu-Li Lin
Research Funding: Milestone Scientific, Inc., Blue Cross Blue Shield
Charles E. Butler
Consulting or Advisory Role: Tela Bio
Anaeze Chidiebele Offodile II
Other Relationship: Blue Cross Blue Shield Association, National Academy of Medicine, Patient Advocate Foundation

No other potential conflicts of interest were reported.
REFERENCES

1. Mariotto A, Yabroff K, Shao Y, et al: Projections of the cost of cancer care in the U.S.: 2010-2020. J Natl Cancer Inst 103:117-128, 2011

2. Zafar SY, Peppercorn JM, Schnag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18:381-390, 2013

3. Lentz R, Benson AB, Kircher S: Financial toxicity in breast care: Prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120:85-92, 2019

4. Ramsey S, Blough D, Kirchhoff A, et al: Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Affairs 32:1114-1152, 2013

5. Gordon LG, Merolli KMD, Lowe A, et al: A systematic review of financial toxicity among cancer survivors: We can’t pay the co-pay. Patient 10:295-309, 2017

6. Fenn KM, Evans SB, McCorkle R, et al: Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 10:332-338, 2014

7. Eli K, Xie B, Wells A, et al: Economic stress among low-income women with cancer: Effects on quality of life. Cancer 112:616-625, 2008

8. Ableson R: Women with Breast Cancer Delay Care When Faced With High Deductibles. New York Times, 2018. https://www.nytimes.com/2018/05/04/health/breast-cancer-insurance-deductibles.html

9. Morgan L: The Financial Burden of Breast Cancer. Forbes, 2020. https://www.forbes.com/sites/nextavenue/2020/01/21/the-financial-burden-of-breast-cancer/

10. DeSantis CE, Ma J, Gaudet MM, et al: Breast cancer statistics, 2019. CA Cancer J Clin 69:438-451, 2019

11. de Souza JA, Yap BJ, Wroblewski K, et al: Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the Comprehensive Score for financial toxicity (COST). Cancer 123:476-484, 2017

12. De Souza JA, Yap BJ, Hlobicky FJ, et al: The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 120:3245-3253, 2014

13. Liu Y, Chen PHC, Krause J, et al: How to read articles that use machine learning: Users’ guides to the medical literature. JAMA 2020; 322: 1806-1816.

14. Alpaydin E: Introduction to Machine Learning (ed 4). Cambridge, MA, The MIT Press, 2020

15. Yu KH, Beam AL, Kohane IS: Artificial intelligence in healthcare. Nat Biomed Eng 2:719-731, 2018

16. Sidey-Gibbons JAM, Sidey-Gibbons CJ: Machine learning in medicine: A practical introduction. BMC Med Res Methodol 19:1-18, 2019

17. Huntington SF, Weiss BM, Vogl DT, et al: Financial toxicity in insured patients with multiple myeloma: A cross-sectional pilot study. Lancet Haematol 2:e408-e416, 2019

18. Boubghan S, Shea M, Kennedy A, et al: Financial toxicity in gynecologic oncology. Gynecol Oncol 154:8-12, 2019

19. White K, de Abreu Lourenco R, Kenny P, et al: Understanding the financial impact of cancer: Examining the “COST” measure in the Australian context. Clin Lymphoma Myeloma Leuk 19:e340, 2019

20. Honda K, Gywail B, Ando M, et al: Prospective study of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer. J Gob Oncol 5:1-8, 2019

21. van Buuren S, Grootvelds-Outshoorn K: mice: Multivariate imputation by chained equations in R. J Stat Softw 45:1-67, 2011

22. Cohen JF, Korevaar DA, Altman DG, et al: STARD 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. BMJ Open 6:e012799, 2016

23. Pfob A, Mehrara B, Nelson J, et al: Towards data-driven decision-making for breast cancer patients undergoing mastectomy and reconstruction: Prediction of individual patient-reported outcomes at two-year follow-up using machine learning. J Clin Oncol 38:520, 2020

24. Pfob A, Sidey-Gibbons C, Tasoulis MK, et al: Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis. J Clin Oncol 38:565, 2020

25. Wolff RF, Moons KGM, Riley RD, et al: PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med 170:51-58, 2019

26. Zafar SY, McNeil RB, Thomas CM, et al: Population-based assessment of cancer survivors’ financial burden and quality of life: A prospective cohort study. J Oncol Pract 11:145-150, 2015

27. Bestvina CM, Zullig LL, Rushing C, et al: Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 10:162-167, 2014

28. Dowling EC, Chawla N, Forsythe LP, et al: Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. Cancer 121:3993-3401, 2013

29. Ramsey SD, Bansal A, Fedorenko CR, et al: Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980-986, 2016

30. Greenup RA, Rushing C, Fish L, et al: Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract 15:e666-e676, 2019

31. Bellavance E, Peppercorn J, Kronsberg S, et al: Surgeons’ perspectives of contralateral prophylactic mastectomy. Ann Surg Oncol 23:2779-2787, 2016

32. Heil J, Pfob A: Patients should be the tipping point of individualizing breast cancer surgery: Commentary on “Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges”. Ann Oncol 31:1264, 2020

33. Regenbogen SE, Veenstra CM, Hawley ST, et al: The personal experience. Oncologist 18:381-390, 2013

34. Woo DC, Stuck AE, Kinsella T, et al: Cancer survivors in the USA. J Cancer Surviv 12:306-315, 2018

35. Greenup RA, Singh J, Shih YC, et al: Cost and complications of local therapies for early-stage breast cancer. J Natl Cancer Inst 109:djw178, 2017

36. Smith BD, Jiang J, Shih YC, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18:381-390, 2013

37. Lee GK, Sheckter CC: Breast reconstruction following breast cancer treatment-2018. JAMA 320:1277-1288, 2018

38. Regenbogen SE, Veenstra CM, Hawley ST, et al: The personal financial burden of complications after colorectal cancer surgery. Cancer 120:3074-3081, 2014

39. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009

40. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35:3618-3632, 2017

41. Smith BD, Jiang J, Shih YC, et al: Cost and complications of local therapies for early-stage breast cancer. J Natl Cancer Inst 109:djw178, 2017

42. Smith BD, Jiang J, Shih YC, et al: Financial toxicity and machine learning.